deferiprone has been researched along with Iron Metabolism Disorders in 8 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Iron Metabolism Disorders: Disorders in the processing of iron in the body: its absorption, transport, storage, and utilization. (From Mosby's Medical, Nursing, & Allied Health Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone was shown to reverse iron deposition in Friedreich's ataxia." | 2.76 | A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. ( Abbruzzese, G; Balocco, M; Barella, S; Bonuccelli, U; Cossu, G; Forni, GL; Galanello, R; Marchese, R; Matta, G; Melis, M; Murgia, D; Ruffinengo, U, 2011) |
| "In one case, we managed to stabilize disease progression for more than 11 years." | 1.72 | Conservative Iron Chelation for Neuroferritinopathy. ( Defebvre, L; Devos, D; Huin, V; Kuchcinski, G; Marchand, F; Moreau, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Marchand, F | 1 |
| Moreau, C | 1 |
| Kuchcinski, G | 1 |
| Huin, V | 1 |
| Defebvre, L | 1 |
| Devos, D | 1 |
| Cossu, G | 2 |
| Abbruzzese, G | 2 |
| Matta, G | 2 |
| Murgia, D | 2 |
| Melis, M | 2 |
| Ricchi, V | 1 |
| Galanello, R | 2 |
| Barella, S | 2 |
| Origa, R | 1 |
| Balocco, M | 2 |
| Pelosin, E | 1 |
| Marchese, R | 2 |
| Ruffinengo, U | 2 |
| Forni, GL | 2 |
| Badat, M | 1 |
| Kaya, B | 1 |
| Telfer, P | 1 |
| Bove, F | 1 |
| Fasano, A | 1 |
| Garringer, HJ | 1 |
| Irimia, JM | 1 |
| Li, W | 1 |
| Goodwin, CB | 1 |
| Richine, B | 1 |
| Acton, A | 1 |
| Chan, RJ | 1 |
| Peacock, M | 1 |
| Muhoberac, BB | 1 |
| Ghetti, B | 1 |
| Vidal, R | 1 |
| Bonuccelli, U | 1 |
| Hayflick, SJ | 1 |
| Hogarth, P | 1 |
| Storti, E | 1 |
| Cortese, F | 1 |
| Di Fabio, R | 1 |
| Fiorillo, C | 1 |
| Pierallini, A | 1 |
| Tessa, A | 1 |
| Valleriani, A | 1 |
| Pierelli, F | 1 |
| Santorelli, FM | 1 |
| Casali, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)"[NCT00907283] | Phase 2 | 20 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| First Pilot Study Evaluating the Life Span of Autologous Cultured Red Blood Cells (cRBC) Generated From Peripheral Stem Cells in Three Healthy Volunteers - Feasibility Study[NCT00929266] | 1 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for deferiprone and Iron Metabolism Disorders
| Article | Year |
|---|---|
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
7 other studies available for deferiprone and Iron Metabolism Disorders
| Article | Year |
|---|---|
Conservative Iron Chelation for Neuroferritinopathy.
Topics: Deferiprone; Disease Progression; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Neuroaxo | 2022 |
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.
Topics: Adult; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Longitudinal S | 2014 |
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; | 2015 |
Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
Topics: Ceruloplasmin; Chelation Therapy; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Met | 2015 |
Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary Ferritinopathy.
Topics: Animals; Apoferritins; Cell Survival; Cells, Cultured; Chelation Therapy; Deferiprone; Disease Model | 2016 |
As iron goes, so goes disease?
Topics: Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Male; Neurodege | 2011 |
De novo FTL mutation: a clinical, neuroimaging, and molecular study.
Topics: Adult; Brain; Cholinergic Antagonists; Deferiprone; Dopamine Agonists; Humans; Iron Metabolism Disor | 2013 |